Skip to main content
Explore URMC

menu

Breast Cancer: Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer (OlympiA)

Research Question:
Will adding treatment with olaparib after the usual care of chemotherapy, surgery and radiation reduce the risk of the cancer coming back?

Basic Study Information

Purpose:
The purpose of this study is to compare the addition of olaparib after the usual care of chemotherapy, surgery, and radiation for your type of cancer. If your cancer is sensitive to hormone treatment, you may receive hormone drugs as part of usual care. In this study, you will get either olaparib or placebo, a pill that looks like the study drug but contains no medication. The use of olaparib could reduce the risk of your cancer coming back but it could also cause side effects.

Location: Cancer Center
Study Web URL:  https://clinicaltrials.gov/ct2/show/NCT02032823?term=NSABP+B55&rank=1
Study Reference #: CBRS-16133

Lead Researcher (Principal Investigator)

Lead Researcher: Alissa Huston

Study Contact Information

Study Coordinator: Kate Corcoran
Phone: (585) 275-7771
Email: Kathryn_Corcoran@URMC.Rochester.edu

Additional Study Details

Return to Search